Edition:
United States

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

18.55USD
3:59pm EST
Change (% chg)

$0.15 (+0.82%)
Prev Close
$18.40
Open
$18.40
Day's High
$18.65
Day's Low
$18.10
Volume
210,829
Avg. Vol
498,001
52-wk High
$24.45
52-wk Low
$3.75

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $1,114.97
Shares Outstanding(Mil.): 60.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.71 15.46
EPS (TTM): -- -- --
ROI: -- -10.20 11.85
ROE: -- -36.19 15.83

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.

Nov 09 2017

UPDATE 1-Dynavax's hep B vaccine gets FDA nod on third try, shares up

Nov 9 Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.

Nov 09 2017

BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults

* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults

Nov 09 2017

Dynavax Hep B vaccine gets FDA approval

Nov 9 Dynavax Technologies Corp's twice-rejected hepatitis B vaccine was approved by the U.S. Food and Drug Administration on Thursday, marking the drug developer's first regulatory approval.

Nov 09 2017

BRIEF-Dynavax reports Q3 loss per share $0.38

* Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

Nov 03 2017

BRIEF-Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist

* Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy

Oct 19 2017

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

Sep 29 2017

BRIEF-Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

* Dynavax Technologies Corp says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

Sep 01 2017

BRIEF-Vectura says global development agreement with Dynavax

* VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281

Aug 16 2017

BRIEF-Dynavax announces exercise in full of over-allotment option

* Dynavax announces exercise in full of over-allotment option and completion of public offering of common stock Source text for Eikon: Further company coverage:

Aug 15 2017

Competitors

Earnings vs. Estimates